Comparison of the incidence of delirium after transfemoral transcatheter aortic valve replacement under monitored anesthesia care with remimazolam versus dexmedetomidine

Not Applicable

Recruiting

• Conditions: Diseases of the circulatory system

• Registration Number: KCT0007245
• Lead Sponsor: Asan Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 8 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 186

Inclusion Criteria

Patients 65 years of age or older who are scheduled to receive transfemoral TAVI under monitored anesthesia care

Exclusion Criteria

?. Patients scheduled for general anesthesia during TAVI
?. Patients undergoing TAVI by a technique other than transfemoral TAVI (e.g., transapical TAVI, transcarotid TAVI, transaortic TAVI, etc.).
?. Patients with preoperative delirium
?. Patients receiving circulatory support before surgery, such as vasopressors, inotropes, and ECMO
?. Patients who have a history of allergy to dexmedetomidine, opioids, or benzodiazepines
?. Patients who are contraindicated to the use of dexmedetomidine, remimazolam, or remifentanil
?. End-stage renal failure patients receiving dialysis
?. Child-Pugh class C liver cirrhosis
?. Patients deemed unsuitable for the study for other reasons by the researcher

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Delirium incidence after TAVI

Secondary Outcome Measures

Name	Time	Method
Post-procedure oxygen therapy duration;The use of vasopressors and/or inotropes;Temporary pacemaker placement;Death within 30 days of procedure;Stroke;Acute kidney injury;Pneumonia;Permanent pacemaker implantation;Length of intensive unit stay;Length of hospital stay